Medinol’s Nirflex
This article was originally published in The Gray Sheet
Executive Summary
Israeli firm's next generation stent is set to enter estimated $500 mil. European market following CE mark approval, announced March 14. The launch "marks the first time Medinol will independently bring a stent mounted on its own delivery system to market," the firm notes. Medinol recently announced its intention to terminate its exclusive, worldwide NIR coronary stent supply agreement with Boston Scientific (1"The Gray Sheet" March 4, 2002, In Brief)...
You may also be interested in...
Boston Scientific/Medinol
Letter purporting to terminate exclusive, worldwide NIR coronary stent supply agreement with Boston Scientific is "improper and invalid," Boston Scientific says in a March 1 release. Medinol alleges breaches of the supply agreement, which Boston Scientific disputes. While the parties remain embroiled in litigation in New York and Israel with respect to the supply agreement and management of Medinol, Boston Scientific says it will challenge the latest action and "considers the supply agreement to be in full force and effect"...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.